<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the abnormal hematopoietic clone burden of the patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and its clinical implication </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The ratio of the metaphase with abnormal karyotypes to the total was regarded as the index of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clonal burden </plain></SENT>
<SENT sid="2" pm="."><plain>Thirteen parameters were assayed and the correlations between these parameters and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone burden were analysed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The clonal burden of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients was (67.4 +/- 36.2)% </plain></SENT>
<SENT sid="4" pm="."><plain>It correlated positively with bone marrow blasts (r = 0.483, P &lt; 0.05), negatively with <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level (r = -0.445, P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The number of blasts, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> and erythrocytes in high clonal burden (&gt;50%) and low clonal burden (&lt; or = 50%) groups were significantly different (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>CD4+ T lymphocytes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> controls were (274.18 +/-71.85) x 10(6)/L and (454.82 +/- 205.88) x 10(6)/L (P &lt; 0.05) respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CD8+ T lymphocytes between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> controls had no difference </plain></SENT>
<SENT sid="8" pm="."><plain>The serum level of IL-2 of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> control groups were (6.29 +/- 3.58) g/L and (3.11 +/- 1.40) microg/L (P &lt; 0.05) respectively; but no difference in the serum level of TNF between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and control groups </plain></SENT>
<SENT sid="9" pm="."><plain>The ratio of CD4+ to CD8+ in high clonal burden patients was 1.90 + 0.52, and in low clonal burden patients was 0.97 +/- 0.44 (P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The clonal burden and deficient T cell immunity are the indicators for predicting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients clinical progression </plain></SENT>
</text></document>